Info

37. Plettenberg H, Stege H, Megahed M, et al.: Ultraviolet A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 41:47, 1999.

38. Jones G, Wilson LD, Fox-Goguen L: Total skin electron beam radiotherapy for patients who have mycosis fun-goides. Hematol Oncol Clin North Am 17:1421, 2003.

39. Fierro MT, Quaglino P, Savoia P, Verrone A, Bernengo MG: Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma 31:583, 1998.

40. Akpek G, Koh HK, Bogen S, et al.: Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophos-phamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 86:1368, 1999.

41. Wollina U, Graefe T, Karte K: Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol 42:40, 2000.

42. Wollina U, Dummer R, Brockmeyer NH, et al.: Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98:993, 2003.

43. Betticher DC, Frey MF, von Rohr A, et al.: High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Ann Oncol 5:57, 1994.

44. Cummings FJ, Kim K, Neiman RS, et al.: Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 9:565, 1991.

45. Grever MR, Bisacia E, Scarborough DA, et al.: An investigation of 2'-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 61:279, 1983.

46. Kurzrock R, Pilat S, Duvic M: Pentostatin therapy of T-cell lymphomas with cutaneous manifestation. J Clin Oncol 17:3117, 1999.

47. Kuzel TM, Hurria A, Samuelson E, et al.: Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 87:906, 1996.

48. Zinzani PL, Baliva G, Magagnoli M, et al.: Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 18:2603, 2000.

49. Dolan ME, McRae BL, Ferries-Rowe E, et al.: O6-Alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents. Clin Cancer Res 5:2059, 1999.

50. Rosen ST, Guitart J, Martone B, et al.: Phase II trial of temozolomide for treatment of mycosis fungoides/ Sezary syndrome. Proc ASCO Abstract 406, 2002.

51. Rook AH, Lessin SR, Jaworsky C, et al.: Immunopathogenesis of cutaneous T-cell lymphoma. Abnormal cytokine production by Sezary cells. Arch Dermatol 129:486-489, 1993.

52. Bunn PA, Foon KA, Ihde DC, et al.: Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 101:484, 1984.

53. Papa G, Tura S, Mandelli F, et al.: Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice? Br J Haematol 79:S48, 1991.

54. Olsen EA, Rosen ST, Vollmer RT, et al.: Interferon alfa-2a in the treatment of cutaneous T cell lymphoma.J Am Acad Dermatol 20:395, 1989.

55. Itri LM, Sherman MI, Palleroni AV, et al.: Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a. J Interferon Res 9:S9, 1989.

56. Kuzel TM, Roenigk HH, Samuelson E, et al.: Effectiveness of interferon alfa-2a combined with photochemother-apy for mycosis fungoides and Sezary syndrome. J Clin Oncol 13:257, 1995.

57. Rupoli S, Barulli S, Guiducci B, et al.: Low dose inter-feron-a2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Hematologica 84:809, 1999.

58. Kessler JF, Jones SE, Levine N, et al.: Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 123:201, 1987.

59. Thomsen K, Molin L, Volden G, et al.: 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 64:563, 1984.

60. Molin L, Thomsen K, Volden G, et al.: Oral retinoids in mycosis fungoides and Sezary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 67:232, 1987.

61. Thomsen K, Hammar H, Molin L, Volden G: Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 69:536, 1989.

62. Duvic M, Martin AG, Kim Y, et al.: Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 137:581, 2001.

63. Duvic M, Hymes K, Heald P, et al.: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. J Clin Oncol 19:2456, 2001.

64. Querfeld C, Rosen ST, Guitart J, et al.: Comparison of selective RAR and RXR retinoid mediated efficacy, tolerance, and survival in refractory cutaneous T-cell lymphoma. J Am Acad Dermatol 51:25, 2004.

65. Yoo EK, Rook AH, Elenitsas R, et al.: Apoptosis induction by ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action. J Invest Dermatol 107:235, 1996.

66. Rook AH, Suchin KR, Kao DMF, et al.: Photopheresis: clinical applications and mechanisms of action. J Invest Dermatol Symp Proc 4:85, 1999.

67. Edelson R, Berger C, Gasparro F, et al.: Treatment of cutaneous T-cell lymphoma by extracorporeal pho-tochemotherapy. Preliminary results. N Engl J Med 316:297, 1987.

68. Heald PW, Perez MI, Christensen I, et al.: Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience. Yale J Biol Med 62:629, 1989.

69. Koh HK, Davis BE, Meola T, Lim HW: Extracorporeal photopheresis for the treatment of 34 patients with cutaneous T-cell lymphoma (CTCL). J Invest Dermatol 102:567, 1994.

70. Gottleib SL, Wolfe JT, Fox FE, et al.: Treatment of cutaneous T-cell lymphoma with extracorporeal pho-tophoresis monotherapy and in combination with recombinant interferon alpha: a 10-year experience at a single institution. J Am Acad Dermatol 35:946, 1996.

71. Suchin KR, Cucchiara AJ, Gottleib SL, et al.: Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol 138:1054, 2002.

72. Wilson LD, Jones GW, Kim D, et al.: Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol 43:54, 2000.

73. Wilson LD, Licata AL, Braverman IM, et al.: Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int JRadiat Oncol Biol Phys 32:987, 1995.

74. LeMaistre CF, Saleh MN, Kuzel TM, et al.: Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 91:399, 1998.

75. Olsen E, Duvic M, Frankel A, et al.: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376, 2001.

76. Duvic M, Kuzel TM, Olsen EA, et al.: Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK®). Clin Lymphoma 2:222, 2002.

77. Foss FM, Bacha P, Osann KE, et al.: Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma 1:298, 2001.

78. Dearden CE, Matutes E, Catovsky D: Alemtuzumab in T-cell malignancies. Med Oncol 19:S27, 2002.

79. Lundin J, Hagberg H, Repp R, et al.: Phase II study of alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) in patients with advanced mycosis fun-goides/Sezary syndrome. Blood 101:4267, 2003.

80. Bigler RD, Crilley P, Micaily B, et al.: Autologous bone marrow transplantation for advanced stage mycosis fun-goides. Bone Marrow Transplant 7:133, 1991.

81. Sterling JC, Marcus R, Burrows NP, Roberts SO: Erythrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow transplantation. Clin Exp Dermatol 20:73, 1995.

82. Olavarria E, Child F, Woolford A, et al.: T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol 114:624, 2001.

83. Russell-Jones R, Child F, Olavarria E, et al.: Autologous peripheral blood stem cell transplantation in tumorstage mycosis fungoides: predictors of disease-free survival. Ann N Y Acad Sci 941:147, 2001.

84. Koeppel MC, Stoppa M, Resbeut D, et al.: Mycosis fungoides and allogenic bone marrow transplantation. Acta Derm Venereol 74:331, 1994.

85. Molina A, Arber D, Murata-Collins JL, et al.: Clinical, cytogenetic and molecular remissions after allogeneic hematopoietic stem cell transplantation for refractory Sézary syndrome and tumor-stage mycosis fungoides. Blood 98:409A, 2001.

86. Guitart J, Wickless S, Oyama Y, et al.: Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch Dermatol 138:1359, 2002.

87. Liu HL, Hoppe RT, Kohler S, et al.: CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 49: 1049, 2003.

88. Paul M, Krowchuk P, Hitchcock M, Jorizzo J: Lymphomatoid papulosis: successful weekly pulse superpotent topical corticosteroid therapy in three pediatric patients. Pediatr Dermatol 13:501, 1996.

89. Vonderheid E, Sajjadian A, Kadin M: Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 34:470, 1996.

90. Wyss M, Dummer R, Dommann S, et al.: Lymphomatoid papulosis-treatment with recombinant interferon alpha-2a and etretinate. Dermatology 190: 288, 1995.

91. Krathen RA, Ward S, Duvic M: Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology 206:142, 2003.

92. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al.: Primary and secondary cutaneous CD30+ lymphoprolif-erative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95:3653, 2000.

93. French LE, Shapiro M, Junkins-Hopkins JM, et al.: Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy. J Am Acad Dermatol 45:914, 2001.

94. Beljaards RC, Meijer CJ, van der Putte SC, et al.: Primary cutaneous T-cell lymphoma: clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma. J Pathol 172:53, 1994.

95. Vermeer MH, Tensen C, van der Stoop PM, et al.: Absence of Th2 cytokine messenger expression in CD30-negative primary cutaneous large T-cell lymphomas. Arch Dermatol 137:901, 2001.

96. Bekkenk MW, Vermeer MH, Jansen PM, et al.: Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood 102:2213, 2003.

97. Hoque SR, Child FJ, Whittaker SJ, et al.: Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol 148:516, 2003.

98. Trautinger F, Knobler R, Willemze R, et al.: EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer 42:1014, 2006.

This page intentionally left blank

Chapter 60

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment